Aeterna Zentaris Inc. (NASDAQ:AEZS) was up 2.3% during trading on Thursday . The stock traded as high as $3.52 and last traded at $3.51, with a volume of 102,717 shares trading hands. The stock had previously closed at $3.43.

Several equities research analysts recently commented on AEZS shares. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Aeterna Zentaris in a research report on Sunday, July 10th. Maxim Group restated a “buy” rating and set a $11.00 target price on shares of Aeterna Zentaris in a research report on Tuesday, July 5th. Finally, Canaccord Genuity restated a “buy” rating and set a $9.00 target price (down previously from $13.00) on shares of Aeterna Zentaris in a research report on Monday, April 4th.

The firm has a 50-day moving average price of $3.45 and a 200-day moving average price of $3.45. The stock’s market cap is $34.89 million.

Aeterna Zentaris Inc is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology, endocrinology and women’s health. The Company has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc Its drug development efforts are focused on two compounds, zoptarelin doxorubicin and Macrilen, which are in clinical development, and on two oncology compounds (an Erk inhibitor and Luteinizing Hormone-Releasing Hormone-disorazol Z product candidates), which are in pre-clinical development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.